MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Dopaminergic modulation of express reaching responses in Parkinson’s disease

    M. Gilchrist, R. Kozak, B. Corneil, P. Macdonald (London, Canada)

    Objective: This study investigates the role of dopamine (DA) in modulation of automatic stimulus-driven responses. We investigated the effect of PD, DA medication, and instruction…
  • 2022 International Congress

    Psychosis in Parkinson’s disease and polymorphisms of the HOMER1 and COMT genes: Is there an association?

    A. Lenka, S. Vadivel, R. Christopher, A. Shyam Sundar, S. Hegde, R. Yadav, P. Pal (Bangalore, India)

    Objective: To investigate if polymorphisms of the HOMER1 and COMT gene are associated with psychosis in Parkinson’s disease (PD). Background: Psychosis is one of the…
  • 2022 International Congress

    Mechanisms and Consequences of Weight Gain After Deep Brain Stimulation of the Subthalamic Nucleus in Patients with Parkinson’s Disease

    J. Steinhardt, L. Lokowandt, D. Rasche, V. Tronnier, T. Münte, S. Meyhöfer, B. Wilms, N. Brüggemann (Lübeck, Germany)

    Objective: To identify stimulation-dependent effects of deep brain stimulation (DBS) on body weight and energy metabolism depending on the electrode position within the subthalamic nucleus…
  • 2022 International Congress

    Longitudinal predictors of quality of life in Parkinson’s disease: analysis of NILS cohort data at four years follow up

    C. Rodriguez-Blazquez, MJ. Forjaz, A. Rizos, P. Martinez-Martin, KR. Chaudhuri (Madrid, Spain)

    Objective: To analyze the change in quality of life (QoL) and its longitudinal predictors in a sample of Parkinson’s disease (PD) patients. Background: Natural progression…
  • 2022 International Congress

    Non-apoptotic caspase-3 activation mediates early synaptic dysfunction of indirect pathway neurons in the parkinsonian striatum

    C. Li, T. Fieblinger, E. Espa, MA. Cenci (Lund, Sweden)

    Objective: We set out to investigate whether caspase-3 plays a role in the loss of dendritic spines and the concomitant synaptic deficits that develop in…
  • 2022 International Congress

    Multimodal assessment of nigrostriatal degeneration in de novo Parkinson’s disease

    M. López-Aguirre, M. Matarazzo, J. Blesa, A. Sánchez-Ferro, M. Hm Monje, J. Obeso, J. Pineda-Pardo (Móstoles, Spain)

    Objective: To study nigrostriatal changes with a multifactorial neuroimaging approach in order to further characterize early abnormalities in Parkinson’s Disease (PD). Background: Imaging techniques allow…
  • 2022 International Congress

    Quality of Life in African American and White Parkinson’s Disease Patients

    D. Hall, S. Anderson, G. Stebbins, L. Barnes, M. Bailey, L. Shulman (Chicago, USA)

    Objective: To determine the quality of life of African American (AA) and White patients with Parkinson’s disease (PD) at the Rush University Medical Center (RUMC)…
  • 2022 International Congress

    Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.

    N. Ayo (Barakaldo, Spain)

    Objective: To analyze the relationship between nutritional intake and weight aspects in 3 groups of patients with Parkinson's disease (PD) who are receiving different pharmacological…
  • 2022 International Congress

    Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2

    K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, M. Scelsi, L. Essioux, A. Monnet, B. van Lier, H. Svoboda, T. Kustermann, W. Zago, T. Nikolcheva, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

    Objective: To determine whether the positive effects of prasinezumab on motor progression measured by Roche PD Mobile Application (PASADENA study Part 1; 0-52 weeks; NCT03100149)…
  • 2022 International Congress

    Effect of CDNF in a novel combination stressor model of Parkinson’s disease

    A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…
  • « Previous Page
  • 1
  • …
  • 478
  • 479
  • 480
  • 481
  • 482
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley